Phaarmasia

Why is Phaarmasia Ltd falling/rising?

As of 01-Sep, Phaarmasia Ltd's stock price is at 95.05, down 4.97% after a trend reversal following six days of gains. Recent poor financial results and weak long-term fundamentals have raised investor concerns, contributing to the stock's decline.

As of 01-Sep, Phaarmasia Ltd's stock price is currently at 95.05, reflecting a decline of 4.97% from the previous trading session. This drop follows a trend reversal after six consecutive days of gains, indicating a shift in market sentiment. Despite opening with a gain of 4.93% today and reaching an intraday high of Rs 104.95, the stock ultimately fell to its current price, which is also its intraday low.<BR><BR>The stock has underperformed its sector by 4.37% today, which may contribute to the negative momentum. Additionally, while the stock has shown strong performance over the past year with a return of 192.46%, recent quarterly results indicate weakness, with net sales falling by 29.8% and profit after tax declining by 33.7% compared to previous quarters. This poor financial performance may have raised concerns among investors, leading to the current decline in stock price.<BR><BR>Furthermore, the company's long-term fundamental strength appears weak, as indicated by an average return on equity (ROE) of only 1.45% and a negative EBIT to interest ratio of -1.15, which suggests difficulties in servicing debt. Although the stock has been trading at a discount compared to its peers and has shown significant returns in the long term, these recent financial results and fundamental weaknesses may be causing investors to reassess their positions, contributing to the stock's current decline.

Who are in the management team of Phaarmasia?

The management team of Phaarmasia includes Vinay Ramakant Sapte (Director), Maneesh R Sapte (Non Executive Director), Y N Bhaskara Rao (Whole-time Director), Rashmi V Sapte (Director), Pravin M. Hegde (Independent Director), Ajit G Jamkhandikar (Independent Director), and Urvashi Bhatia (Company Secretary & Compliance Officer). Each member contributes to the company's governance and management.

The management team of Phaarmasia includes the following individuals:<BR><BR>1. **Vinay Ramakant Sapte** - Director<BR>2. **Maneesh R Sapte** - Non Executive Director<BR>3. **Y N Bhaskara Rao** - Whole-time Director<BR>4. **Rashmi V Sapte** - Director<BR>5. **Pravin M. Hegde** - Independent Director<BR>6. **Ajit G Jamkhandikar** - Independent Director<BR>7. **Urvashi Bhatia** - Company Secretary & Compliance Officer<BR><BR>Each member plays a significant role in the governance and management of the company.

What does Phaarmasia do?

Phaarmasia Ltd is a micro-cap manufacturing company specializing in hormonal products, particularly oral contraceptives and iron tablet combipacks. As of June 2026, it reported net sales of 8 Cr and a market cap of INR 69 Cr.

Overview:<BR>Phaarmasia Ltd is a manufacturing company specializing in hormonal products, specifically oral contraceptive tablets and combipacks with iron tablets, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>History:<BR>Incorporated in 1981, Phaarmasia Ltd established its Unit-II in 1993-94. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 8 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 0 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 69 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 32.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.04<BR>- Return on Equity: 19.76%<BR>- Price to Book: 6.08<BR><BR>Contact Details:<BR>- Address: 16 Phase III, I D A Jeedimetla Hyderabad Telangana : 500055<BR>- Tel: 91-40-23095002/23095690<BR>- Email: phaarmasia@yahoo.com / phaarmasia@gma<BR>- Website: http://www.phaarmasia.com

Who are the peers of the Phaarmasia?

Phaarmasia's peers include Source Natural, Bharat Immunolog, Shelter Pharma, Biofil Chemicals, Mangalam Drugs, Vasundhara Rasy., Parmax Pharma, Vilin Bio Med, and Ajooni Biotech. Phaarmasia has the highest 1-year return at 192.54%, while Bharat Immunolog has the lowest at -27.90%.

Peers: The peers of Phaarmasia are Source Natural, Bharat Immunolog, Shelter Pharma, Biofil Chemicals, Mangalam Drugs, Vasundhara Rasy., Parmax Pharma, Vilin Bio Med, and Ajooni Biotech.<BR><BR>Quality Snapshot: Excellent management risk is observed at Shelter Pharma, while Average management risk is found at Source Natural, Biofil Chemicals, and Vasundhara Rasy., and the rest have Below Average management risk. Good growth is seen at Shelter Pharma and Ajooni Biotech, Average growth at Phaarmasia and Vilin Bio Med, while Below Average growth is noted for Source Natural, Bharat Immunolog, Biofil Chemicals, Mangalam Drugs, Parmax Pharma, and the rest. Excellent capital structure is present at Shelter Pharma, Good capital structure is observed at Source Natural and Biofil Chemicals, while Below Average capital structure is noted for Phaarmasia, Bharat Immunolog, Mangalam Drugs, Parmax Pharma, Vilin Bio Med, and the rest.<BR><BR>Return Snapshot: Phaarmasia has the highest 1-year return at 192.54%, while Bharat Immunolog has the lowest at -27.90%. Compared to its peers, Phaarmasia's return is significantly higher. Additionally, peers such as Bharat Immunolog, Shelter Pharma, Biofil Chemicals, Mangalam Drugs, and Parmax Pharma have negative six-month returns.

How big is Phaarmasia?

As of 31st August, Phaarmasia Ltd has a market capitalization of 69.00 Cr, with recent net sales of 48.61 Cr and a net profit of 17.65 Cr. Shareholder's funds are 8.74 Cr, and total assets amount to 21.47 Cr as of March 2025.

As of 31st August, Phaarmasia Ltd has a market capitalization of 69.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Phaarmasia reported Net Sales of 48.61 Cr and a Net Profit of 17.65 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 8.74 Cr and Total Assets of 21.47 Cr.

Which are the latest news on Phaarmasia?

Should I buy, sell or hold Phaarmasia Ltd?

Are Phaarmasia Ltd latest results good or bad?

Phaarmasia Ltd's latest Q4 FY26 results are concerning, showing a net loss of -₹0.70 crore and a 51.84% drop in revenue to ₹7.73 crore, despite a year-on-year revenue increase. The negative operating margin and significant decline in profitability indicate serious operational challenges.

Phaarmasia Ltd's latest results for Q4 FY26 indicate a troubling performance. The company reported a net profit of -₹0.70 crore, a significant decline from a profit of ₹16.27 crore in the previous quarter (Q3 FY26). This represents a drastic drop in profitability, highlighting operational challenges.<BR><BR>Revenue also saw a sharp decrease, falling by 51.84% quarter-on-quarter to ₹7.73 crore, although it did show a year-on-year growth of 42.36% compared to ₹5.43 crore in Q4 FY25. The operating margin turned negative at -8.67%, down from a positive 5.23% in the prior quarter, indicating severe operational difficulties.<BR><BR>Overall, the results reflect extreme volatility and a lack of consistent operational momentum, raising concerns about the company's sustainability and future performance. The sharp reversal in profitability and revenue, combined with negative return metrics, suggests that the latest results are indeed bad for Phaarmasia Ltd.

When is the next results date for Phaarmasia Ltd?

The next results date for Phaarmasia Ltd is 13 August 2026.

The next results date for Phaarmasia Ltd is scheduled for 13 August 2026.

Is Phaarmasia overvalued or undervalued?

As of November 21, 2025, Phaarmasia is considered overvalued with a high PE ratio of 42.96 and lagging stock performance, compared to peers like Sun Pharma and Cipla, which have lower valuation metrics.

As of 21 November 2025, Phaarmasia's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently considered overvalued based on its high PE ratio of 42.96, an EV to EBIT ratio of 33.08, and a Price to Book Value of 3.12. In comparison to its peers, Sun Pharma has a PE ratio of 36.98 and an EV to EBITDA of 24.43, while Cipla is valued attractively with a PE of 22.45 and an EV to EBITDA of 15.88.<BR><BR>Given these metrics, Phaarmasia appears overvalued in the current market environment. The company's recent stock performance has lagged behind the Sensex, with a year-to-date return of only 1.20% compared to the Sensex's 9.08%, further reinforcing the assessment of overvaluation.

How has been the historical performance of Phaarmasia?

Phaarmasia's historical performance has shown a decline in net sales and profitability, with net sales dropping from 30.59 Cr in March 2024 to 24.37 Cr in March 2025, and operating profit worsening from -0.17 Cr to -1.26 Cr during the same period. Total assets and liabilities also decreased, leading to a reduced book value per share from 8.87 to 6.58.

Answer:<BR>The historical performance of Phaarmasia shows a fluctuating trend in net sales and profitability over the years, with a notable decline in recent periods.<BR><BR>Breakdown:<BR>Phaarmasia's net sales peaked at 30.59 Cr in March 2024 but fell to 24.37 Cr by March 2025. The total operating income followed a similar pattern, decreasing from 30.59 Cr in March 2024 to 24.37 Cr in March 2025. The company's total expenditure, excluding depreciation, also decreased from 31.42 Cr in March 2024 to 26.38 Cr in March 2025, yet the operating profit (PBDIT) remained negative, worsening from -0.17 Cr in March 2024 to -1.26 Cr in March 2025. Profit before tax also declined, moving from -0.55 Cr in March 2024 to -1.60 Cr in March 2025, while profit after tax showed a similar trend, dropping from -0.52 Cr to -1.59 Cr in the same period. The company's total assets decreased from 31.37 Cr in March 2024 to 21.47 Cr in March 2025, with total liabilities also declining from 31.37 Cr to 21.47 Cr. The book value per share adjusted down from 8.87 in March 2024 to 6.58 in March 2025, reflecting the overall downward trend in financial performance.

Who are the top shareholders of the Phaarmasia?

The top shareholder of Phaarmasia is Maneesh Pharmaceuticals Limited, with a 44.22% stake. Individual investors, led by Madhavi Pradeep Save at 1.73%, collectively own 26.18%, while there are no mutual funds or foreign institutional investors involved.

The top shareholders of Phaarmasia include Maneesh Pharmaceuticals Limited, which holds the largest stake at 44.22%. The majority of the company's shares are held by promoters, and there are no pledged promoter holdings. In terms of public shareholders, Madhavi Pradeep Save is the highest individual investor, holding 1.73%. Additionally, individual investors collectively own 26.18% of the company. There are currently no mutual funds or foreign institutional investors holding shares in Phaarmasia.

What is the technical trend for Phaarmasia?

As of June 5, 2025, Phaarmasia's trend is mildly bearish, with mixed signals from indicators like MACD and Bollinger Bands, suggesting a cautious approach due to prevailing bearish sentiment in the longer term.

As of 5 June 2025, the technical trend for Phaarmasia has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by several key indicators. The MACD on a weekly basis is mildly bullish, but the monthly MACD remains bearish, indicating mixed signals. The Bollinger Bands are mildly bearish on both weekly and monthly time frames, suggesting a potential continuation of the downward trend. Moving averages on a daily basis are bearish, reinforcing the negative outlook. The KST shows a mildly bullish signal weekly but is bearish monthly, while Dow Theory indicates a mildly bearish trend weekly and mildly bullish monthly. Overall, the mixed signals across different indicators suggest a cautious approach, with the bearish sentiment prevailing in the longer term.

Has Phaarmasia declared dividend?

No Dividend History Available